Eledon Pharmaceuticals Long-term Phase 2 BESTOW Trial Results at ATC Transcript
Good morning, ladies and gentlemen, and welcome to The American Transplant Congress Data Update Call. (Operator Instructions) This call is being recorded on Monday, June 22, 2026. I would now like to turn the conference over to Paul Little, Chief Financial Officer. Please go ahead.
Chief Executive Officer, Steve Perrin, our President and Chief Scientific Officer; and Dave Hovland, our Chief Regulatory Officer. Earlier today, Eledon issued a press release detailing the updated clinical results presented at the American Transplant Congress. You may access the release and this presentation under the Investors tab on our company's website at eladon.com.
I would like to remind everyone that statements made during the conference call relating to Eledon's expected future performance, future business plans, our future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
